University News

Working together

UB Pharmacy Programs

Scientific quality of UB pharmacy programs led to alliance with Pfizer. (Photo: KC Kratt, MFA ’84)

The School of Pharmacy and Pharmaceutical Sciences has announced a “strategic alliance” with Pfizer Inc. that will provide up to $7.5 million toward development at UB of a Center of Excellence in Pharmacokinetics and Pharmacodynamics.

Pfizer will provide the pharmacy school with $1.5 million per year for three years, with possible renewal for an additional two years, to hire new faculty members, increase doctoral student enrollment, expand the school’s postdoctoral fellowship program and support performance of cutting-edge research in pharmacokinetics and pharmacodynamics.

“UB’s strong partnership with Pfizer is built on the success of many pharmaceutical sciences graduates within their organization,” says Wayne K. Anderson, dean of the School of Pharmacy and Pharmaceutical Sciences. “We are one of the nation’s top pharmacy schools, and Pfizer considered the quality of science that we produce to be a driving factor in creating this strategic alliance. This partnership will enable us to play an even larger role as a leading source of research and training in pharmaceutical sciences.”